Lever
Lifestyle
- Regular liver health monitoring
- Avoiding alcohol and hepatotoxic substances
Blutwerte · Marker
AFP
Alpha-Fetoprotein · AFP
Tumormarker & Screening
- Einheit:
- ng/mL
AFP measures the level of alpha-fetoprotein, a glycoprotein produced by the liver and yolk sac during fetal development.
Reference Ranges
Reference
0–10ng/mL
0
10
LowNormalHigh
Reference
Unit · ng/mLReference ranges may vary slightly depending on the laboratory and population studied.
Overview
Übersicht
Alpha-fetoprotein (AFP) is a glycoprotein primarily produced during fetal development by the liver and yolk sac. In adults, AFP levels are typically low, but they can rise in response to liver damage, regeneration, or malignancy, particularly hepatocellular carcinoma (HCC). Clinically, AFP is a well-established biomarker for HCC screening and monitoring, and it is used to predict prognosis and treatment response. Elevated AFP levels are also associated with certain germ cell tumors. Researchers have found that AFP, along with other biomarkers like AFP-L3 and DCP, can improve the prediction of HCC recurrence, especially post-liver transplantation. In the context of athletic performance, biohacking, or longevity, AFP itself is not directly relevant, but its role in indicating liver health could be indirectly important. Elevated AFP could signal liver stress or damage, which might be pertinent to athletes or biohackers monitoring their liver function. Caveats include the influence of liver necroinflammation, the etiology of liver disease, and the need for standardized cut-off values. AFP levels can be affected by pregnancy, as it is naturally elevated during this period, and by certain non-malignant liver conditions, which can confound interpretation. No specific time-of-day or fasting requirements are noted for AFP testing, but consistent testing conditions are recommended for reliable monitoring.
Klinische Bedeutung
Elevated AFP levels in adults can indicate liver diseases such as hepatocellular carcinoma or certain germ cell tumors. It is used to monitor disease progression and treatment efficacy, particularly in liver cancer.
Dynamics
Trend Interpretation
Rising Values
Progressively rising AFP values suggest worsening liver function or tumor progression. Retest every 4-6 weeks if outside the optimal range.
Falling Values
Decreasing AFP levels may indicate effective treatment or tumor regression.
Re-test Interval
4 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Hepatocellular carcinoma
- Germ cell tumors
- Liver cirrhosis
- Chronic hepatitis
- Pregnancy
Cause
Low Levels
- Normal postnatal levels
- Effective cancer treatment
- Liver function normalization
- Non-pregnant state
Protocol
How to Optimize
Lever
Nutrition
- Diet rich in antioxidants
- Adequate hydration
Note:
Consult a healthcare provider for personalized advice, especially if liver disease is suspected.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Annually for individuals at risk of liver disease, more frequently if monitoring known conditions.
Interfering Factors
- Pregnancy
- Liver inflammation
- Recent liver injury
Open Research Questions
Current research suggests that the optimal cut-off levels for AFP in different clinical contexts, such as liver disease and pregnancy, remain debated, particularly regarding its accuracy influenced by liver necroinflammation and disease etiology. Researchers have not yet established standardized reference ranges for AFP and its combinations with other biomarkers like PIVKA-II in diverse populations. Unanswered clinical questions include the effectiveness of AFP in detecting early HCC in AFP-negative patients and the ideal pre-transplant therapy for high-risk individuals.
19 Research Publications
1,359
Total Citations
4
Human/RCT
5.1
Avg. Influence
2025
Latest
Sort
Filter
01Top
#01
The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.
Tayob Nabihah, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023
HumanInfluence17.0
189
Researchers conducted a phase 3 study to evaluate the performance of GALAD, which includes alpha-fetoprotein (AFP), in detecting hepatocellular carcinoma (HCC). The study found that while GALAD improved sensitivity, it also increased false-positive results compared to AFP alone.
Key findings
- 01GALAD demonstrated a higher true positive rate for detecting HCC compared to individual biomarkers.
- 02The use of GALAD resulted in an increased rate of false positives.
- 03The performance of GALAD was not significantly better than that of AFP-L3 alone or the HES scoring system.
02Top
#02
Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders.
ReviewInfluence3.0
153
This study focused on the differential diagnosis of elevated alpha-fetoprotein (AFP) levels in hepatocellular carcinoma (HCC) and other disorders. Researchers found that combining AFP-L3 with DCP can improve risk assessment for HCC. The findings suggest that monitoring these biomarkers can help predict disease progression and recurrence.
03Top
#03
PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
HumanInfluence6.0
147
This study assessed the potential of PIVKA-II as a complementary biomarker to alpha-fetoprotein (AFP) for diagnosing hepatocellular carcinoma (HCC). Researchers found that combining PIVKA-II with AFP significantly improved diagnostic efficiency, especially for AFP-negative HCC patients.
04
#04
Alpha-fetoprotein: a renaissance.
ReviewInfluence3.0
140
Researchers summarized the advancements in understanding alpha-fetoprotein (AFP) over the past 50 years, noting its significance in embryonic development and cancer. The study found that new technologies have reignited interest in AFP as a tumor-specific biomarker.
05
#05
Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma.
ReviewInfluence6.0
139
This review examined the effects of alpha-fetoprotein (AFP) on the progression of hepatocellular carcinoma (HCC). Researchers found that elevated AFP levels are common in HCC patients and that AFP plays a complex role in regulating cell proliferation and immune response. The study suggests further exploration of AFP's role in HCC development.
06
#06
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.
UnknownInfluence5.0
124
Researchers evaluated the combined use of PIVKA-II and AFP for monitoring hepatocellular carcinoma (HCC) in the Asia-Pacific region. The study found that PIVKA-II could enhance detection of early HCC, particularly in AFP-negative patients, though further evidence is needed for routine use.
07
#07
AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.
Norman Joshua S, et al. · Journal of hepatology · 2023
HumanInfluence11.0
120
This study investigated the predictive capabilities of AFP-L3 and DCP in assessing hepatocellular carcinoma (HCC) recurrence after liver transplantation. Researchers found that a dual-biomarker combination of AFP-L3 and DCP significantly outperformed AFP alone in predicting early HCC recurrence.
Key findings
- 01AFP-L3 and DCP outperformed AFP in predicting liver cancer recurrence after transplantation.
- 02A combination of AFP-L3 ≥15% and DCP ≥7.5 predicted 61.1% of recurrences.
- 03Patients with high levels of both biomarkers had a significantly lower chance of remaining cancer-free after three years.
08
#08
Alpha-fetoprotein: a review.
ReviewInfluence2.0
119
This review discussed the historical and clinical significance of alpha-fetoprotein (AFP) in fetal development and its role in detecting certain abnormalities. Researchers highlighted AFP's utility in monitoring malignancies and the importance of standard protocols for its measurement.
09
#09
Alpha-fetoprotein for Diagnosis, Prognosis, and Transplant Selection.
Trevisani Franco, et al. · Seminars in liver disease · 2019
ReviewInfluence2.0
68
This review analyzed the utility of alpha-fetoprotein (AFP) as a biomarker for hepatocellular carcinoma (HCC) diagnosis and prognosis. Researchers found that AFP remains the most utilized biomarker for HCC and is valuable in selecting candidates for liver transplantation. The study emphasizes its importance in predicting cancer recurrence.
Key findings
- 01AFP remains the most widely used biomarker for diagnosing hepatocellular carcinoma (HCC).
- 02The study emphasizes AFP's significance in assessing prognosis for patients receiving treatment for HCC.
- 03Incorporating AFP into transplant criteria can help identify patients at higher risk of cancer recurrence.
10
#10
Alpha-fetoprotein: Past, present, and future.
ReviewInfluence2.0
64
This review examined the role of alpha-fetoprotein (AFP) in immune regulation and its utility as a biomarker for hepatocellular carcinoma (HCC). Researchers found that AFP is a powerful prognostic biomarker for HCC and plays important roles in immune modulation, indicating its potential as a therapeutic target.
Publication Trend
Research publications about AFP over time
9totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer